Review Article
Phosphate Frustration: Treatment Options to Complement Current Therapies
Table 1
Efficacy of phosphate binders in phase 3 trials.
| Reference | Number of patients | Duration of treatment (weeks) | Binders | Mean baseline phosphate levels (mg/dL) | Mean baseline phosphate levels at the end of treatment (mg/dL) | Percentage decrease in phosphate levels (%) |
| Emmett et al. [34] | 91 | 2 | Calcium acetate | 7.3 | 5.9 | 19 | Placebo (comparator) | 7.3 | 7.3 | 0 |
| Floege et al. [35] | 1041 | 24 | Sucroferric oxyhydroxide | 7.7 | 5.6 | 27 | Sevelamer (comparator) | 7.4 | 5.3 | 28 |
| Bleyer et al. [36] | 84 | 8 | Sevelamer hydrochloride | 8.4 | 6.5 | 24 | Calcium acetate (comparator) | 8.0 | 5.9 | 26 |
| Mehrotra et al. [37] | 126 | 8 | Lanthanum carbonate | 7.7 | 5.9 | 23 | Placebo (comparator) | 7.4 | 7.9 | (6) |
| Akebia therapeutics, data on file [38] | 292 | 52 | Ferric citrate | 7.4 | 5.4 | 27 | Sevelamer and/or calcium acetate (comparator) | 7.6 | 5.4 | 29 |
|
|